Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979638 · ClinicalTrials.gov registry record · Phase 2
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
A Phase 2 study, sponsored by Bellus Health Inc. - a GSK company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT03979638 is a Phase 2 study that was terminated before completion, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 68 participants.
The verdict
NCT03979638, a Phase 2 study, was terminated before completion, sponsored by Bellus Health Inc. - a GSK company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
Interventions
- DRUG Placebo
- DRUG BLU-5937
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2019-07-10 |
| Est. Completion | 2020-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03979638
The ClinicalTrials.gov registry entry for NCT03979638 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03979638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03979638 about?
NCT03979638 is a clinical study titled "A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough". This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
What is the current status of trial NCT03979638?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2019-07-10. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT03979638?
The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).
Who is sponsoring clinical trial NCT03979638?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.